Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Hedgehog pathway inhibitors (HPI) inactivating SMO 1, have become first line treatment for patients with locally advanced BCC (laBCC). HPI safety and efficacy have been shown in clinical trials2,3. Nevertheless, common adverse events lead to treatment discontinuation.
Description
Keywords
Anilides, Carcinoma, Basal Cell, Drug Resistance, Neoplasm, Humans, Mutation, Neoplasm Recurrence, Local, Pyridines, Skin Neoplasms
Journal Title
J Eur Acad Dermatol Venereol
Conference Name
Journal ISSN
0926-9959
1468-3083
1468-3083
Volume Title
33
Publisher
Wiley
Publisher DOI
Rights
All rights reserved